糖尿病骨质疏松大鼠破骨细胞的改变

目的:采用腹腔注射链脲佐菌素 切除双侧卵巢复合方法建立绝经后糖尿病骨质疏松大鼠模型,观察糖尿病骨质疏松大鼠破骨细胞的改变。方法:实验于2003-12/2004-08在河北医科大学第三医院中心实验室完成。①实验材料:选用2.5～3个月龄清洁级雌性Wistar大鼠60只。②实验分组:完全随机设计分为6组:正常对照组、正常假手术组及正常双侧卵巢切除组均为8只;糖尿病对照组、糖尿病假手术组及糖尿病双侧卵巢切除组均为12只。③实验干预:采用链脲佐菌素诱导制备糖尿病大鼠模型1周后,将大鼠麻醉结扎输卵管切除卵巢。假手术组大鼠不作卵巢切除,余操作同去卵巢组。卵巢切除后0,2,4,8周随机选择各组大鼠1只,收集骨髓,进行体外骨髓破骨细胞样细胞的培养。④实验评估:切除双侧卵巢后2,4,8周时测量各组大鼠体质量、血糖;细胞培养7d后,进行细胞固定和抗酒石酸酸性磷酸酶染色(抗酒石酸酸性磷酸酶染色阳性且细胞核≥3个的细胞认定为破骨细胞样细胞);倒置显微镜计数破骨细胞样细胞数量。结果:制成糖尿病模型及切除卵巢后,3组糖尿病大鼠死亡7只,进入结果分析53只。①各组大鼠血糖和体质量的变化:切除卵巢0,2,4,8周,3组糖尿病大鼠血糖均高于正常组(P<0.01),体质量均低于正常组(P<0.01);4周时,正常双侧卵巢切除组体质量高于同期正常对照组和正常假手术组;糖尿病双侧卵巢切除组体质量在2,4,8周时均高于同期糖尿病对照组和糖尿病假手术组(4周P<0.05,8周P<0.01)。②切除卵巢后各组大鼠体外培养的破骨细胞样细胞形成的变化:糖尿病双侧卵巢切除大鼠破骨细胞多于糖尿病大鼠及正常去卵巢大鼠,且破骨细胞数量随着去卵巢的时间和糖尿病病程延长而增加。③骨髓来源的体外破骨细胞样细胞的形成与血糖、糖尿病病程及去卵巢时间的相关性分析:破骨细胞数量与糖尿病病程呈正相关,而与血糖增高的程度无关(r=-0.537;P=0.109)。结论:①卵巢切除对大鼠的血糖无显著影响,对大鼠体质量的影响被糖尿病减弱,在糖尿病早期破骨细胞样细胞的形成已有增加。②破骨细胞形成增加可能是绝经后糖尿病骨质疏松的原因之一。     

差速贴壁技术对大鼠脑皮质星形胶质细胞纯化率的影响

目的:观察差速贴壁技术对星形胶质细胞纯化率的影响,旨在建立一套可靠的大鼠脑皮质星形胶质细胞的取材分离、纯化培养技术。方法:实验于2006-06/08在泰山医学院生命科学研究所完成。实验材料:出生2～3d的Wistar大鼠,雌雄不拘,由泰山医学院生命科学研究所实验动物中心提供。实验方法:选用出生二三天的Wistar大鼠进行脑皮质星形胶质细胞原代培养。实验分两组培养:常规培养组和差速贴壁培养组。差速贴壁培养组分别于15,30min取出,轻轻翻转培养瓶,将上清液移至另一培养瓶中,放入培养箱中继续培养。7～10d后传代,待细胞分层生长后,置于37℃摇床中250r/min振荡18h,倒掉上清液,D-Hank’s液洗3次后,加入0.25%胰酶消化,倒置显微镜下观察,待细胞突起回缩后加入含血清的培养基终止消化,用吸管反复吹打使细胞从瓶壁上脱落,细胞悬液1000r/min离心5min后,弃上清液,加入含体积分数为0.2血清的DMEM培养基混悬沉淀,接种入预先涂有L-多聚赖氨酸的培养瓶中继续培养。采用双重免疫荧光法鉴定星形胶质细胞纯度,测定积分吸光度值判断星形胶质细胞的生长状况。结果:①应用差速贴壁技术培养星形胶质细胞可明显提高星形胶质细胞纯度[常规培养组:(82±3)%,差速贴壁培养组15min:(94±2)%,差速贴壁培养组30min:(95±2)%,P<0.01]。差速贴壁需要充分的时间,15min组和30min组在提高星形胶质细胞纯度方面无明显差别。②差速贴壁培养组星形胶质细胞积分吸光度值高于常规培养组(常规培养组:528±25,差速贴壁培养组15min:972±17,差速贴壁培养组30min:996±35,P<0.05)。结论:①差速贴壁技术可明显提高星形胶质细胞纯化度,并且星形胶质细胞生长状态明显优于常规培养方法。②最佳差速贴壁时间为15min,过长差速贴壁时间对提高星形胶质细胞纯度无明显影响。     

High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia

Lipid targets can be difficult to attain in familial hypercholesterolaemia. To compare atorvastatin with simvastatin- fenofibrate and simvastatin-cholestyramine therapy, we studied 54 patients with familial hypercholesterolaemia over periods of 2-6 months on each therapeutic regimen. The atorvastatin regimen reduced total cholesterol by 41.2 +/- 11.2%, LDL by 45.6 +/- 15.5%, triglycerides by 33.8 +/- 24.8%, and increased HDL by 2.3 +/- 37.0%. Simvastatin- fenofibrate therapy achieved reductions of 33.9 +/- 8.5% in cholesterol, 42.0 +/- 12.2% in LDL, 34.7 +/- 38.3% for triglycerides, and a 25.4 +/- 55.1% increase in HDL. Simvastatin-cholestyramine gave a reduction of 31.3 +/- 11.8% in cholesterol, 36.0 +/- 14.4% in LDL, 13.7 +/- 36.3% in triglycerides, and a 1.1 +/- 30.3% rise in HDL. The atorvastatin regimen was marginally but not significantly better than simvastatin-fenofibrate in improving the LDL:HDL ratio, LDL:apoB and and apolipoprotein B:A1 ratios. Eleven patients (20.4%) had side- effects: two discontinued atorvastatin due to side-effects; two patients had rashes; six had myalgia and two had diarrhoea. Gastrointestinal side-effects were described in 16 (30.1%) patients on simvastatin-cholestyramine therapy and four cases of myalgia (11.2%) were seen with simvastatin-fenofibrate. In nine patients on atorvastatin (20.4%) a 30% or greater fall in HDL was observed, compared to five patients with resin therapy (9.2%) and two with fibrate therapy (5.5%). There were no significant differences in liver or muscle biochemistry between the regimens, but atorvastatin did raise transaminase and creatine kinase concentrations significantly compared to pre-treatment values (p = 0.001). Atorvastatin significantly improves the lipid profile in most patients compared with other regimens. It has a comparable incidence of side-effects to combination therapy regimens.      

The protein/creatinine index. A semiquantitative assessment of 24-hour protein excretion

The 24-hour protein excretion is important in estimating the severity of a renal lesion and is used extensively for diagnostic and prognostic purposes and also to follow the response of patients to treatment. The disadvantages of timed 24-hour collections are that they are cumbersome, inconvenient, expensive, and unreliable in up to one-third of cases. The aim of this study was to correlate the protein/creatinine (P/cr) index in a random spot urine sample and protein excretion in a 24-hour urine sample from the same patient. The P/cr index was derived as follows: (Formula: see text). In the 34 patients investigated there was a highly significant correlation (r = 0.9017) between the P/cr index and 24-protein excretion. The P/cr index is a useful and quick method of assessing proteinuria in most patients with renal disease.     

消旋棉酚拆分的研究——Ⅲ.胺缩棉酚理化性质的研究

本文报道消旋棉酚与15种不同结构的光学活性胺缩合产物的薄层色谱性质和核磁共振氢谱数据,以及8个光学活性胺与光学活性棉酚缩合物的光学稳定性,并探讨了结构与这些性质的关系。     

Patient with malignant hypertension alive after 25 years. A case report

An indian man presented in 1960 with malignant hypertension. He was treated with guanethidine (Ismelin; Ciba), when it was first introduced onto the pharmaceutical market, in combination with other hypotensive agents. Therapeutic compliance was excellent and after 25 years of hypotensive therapy the patient still has a good quality of life.     

Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis—old method, new discovery

A 23-year-old Chinese man with dermatomyositis associated calcinosis cutis received electric shock wave lithotripsy (ESWL) as an alternate to a conventional pharmacological regimen to reduce pain associated with the complications of subcutaneous calcinosis nodules. He became symptom and opioid free after two courses of ESWL. No significant adverse effect had been noted. ESWL may serve as a means of pain killing in patients suffering from debilitating pain caused by complicated calcinosis cutis.